| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human ANGPTL7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于ANGPTL7抗体的代表性文献信息(文献为虚拟示例，实际研究中请核实具体文献)：
---
1. **文献名称**: *ANGPTL7 Antibody Therapy Reduces Intraocular Pressure in Glaucoma Models*
**作者**: Smith A et al.
**摘要**: 研究报道了一种特异性靶向ANGPTL7的单克隆抗体，通过抑制ANGPTL7的活性显著降低青光眼动物模型的眼压，揭示了ANGPTL7作为青光眼治疗靶点的潜力。
---
2. **文献名称**: *Structural Characterization of ANGPTL7 Antibody Epitopes by Cryo-EM*
**作者**: Zhang L et al.
**摘要**: 利用冷冻电镜解析了ANGPTL7蛋白与治疗性抗体的复合物结构，明确了抗体结合表位，为优化抗体药物设计提供了结构生物学依据。
---
3. **文献名称**: *ANGPTL7 Neutralizing Antibody Attenuates Fibrosis in Corneal Injury*
**作者**: Chen Y et al.
**摘要**: 实验证明中和ANGPTL7的抗体可抑制角膜损伤后的纤维化过程，机制可能与阻断TGF-β信号通路相关，提示其在抗纤维化治疗中的应用价值。
---
如需具体文献，建议在PubMed或Web of Science中搜索关键词“ANGPTL7 antibody” + “therapy/structure/function”筛选近年高质量论文。
ANGPTL7 (angiopoietin-like protein 7) is a secreted glycoprotein belonging to the angiopoietin-like family, which plays roles in angiogenesis, lipid metabolism, and tissue remodeling. Primarily expressed in ocular tissues, such as the cornea, trabecular meshwork, and ciliary body, ANGPTL7 is implicated in regulating intraocular pressure (IOP) and extracellular matrix (ECM) dynamics. Dysregulation of ANGPTL7 has been linked to glaucoma, a leading cause of irreversible blindness, due to its potential influence on aqueous humor outflow and fibrotic pathways.
Antibodies targeting ANGPTL7 are experimental tools designed to study its function or modulate its activity. Research suggests that inhibiting ANGPTL7 with monoclonal antibodies may reduce IOP by enhancing trabecular meshwork permeability or suppressing ECM deposition, offering therapeutic potential for glaucoma. Additionally, ANGPTL7 antibodies are used in immunohistochemistry, ELISA, and Western blotting to explore its expression patterns and interactions in ocular and systemic diseases.
While preclinical studies highlight its promise, clinical applications remain under investigation. Challenges include optimizing antibody specificity, delivery to target tissues, and understanding systemic effects, given ANGPTL7’s dual roles in metabolic and fibrotic pathways. Current efforts focus on validating these antibodies as both research reagents and potential therapeutics for glaucoma and fibrosis-related conditions.
×
